Aybintio (bevacizumab biosimilar) / Samsung, 3SBio, Mundipharma - LARVOL DELTA

Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain Metastases (clinicaltrials.gov) - P2 | N=7 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | N=112 ➔ 7 | Trial completion date: Jul 2025 ➔ Jul 2026 | Trial primary completion date: Jul 2025 ➔ Feb 2025

Enrollment change • Trial completion date • Trial primary completion date • Brain Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Novel Halotolerant Bacteria from Saline Environments: Isolation and Biomolecule Production. (PubMed, BioTech (Basel)) - "Based on their phenotypic and molecular characteristics, the four halotolerant bacteria were identified as Halomonas elongata SB8, Bacillus altitudinis CN6, Planococcus rifietoensis CN8, and Halomonas stenophila IB5...rifietoensis CN8 produced the highest carotenoid concentration with antifungal and antimicrobial activity. Exploring these organisms opens new pathways for bioremediation, industrial bioprocessing, and sustainable biomolecule production."

Journal

The Impact of State Legislation on the Incidence of Births With Congenital Anomalies in Texas. (PubMed, Ann Surg) - "With the passage of SB8, the incidence of births with congenital anomalies increased substantially in Texas. Further research is warranted on the long-term implications of this increase."

Journal

Time Series Analysis of Infant Mortality Disaggregated by Race, Ethnicity and Specific Causes After 6-Week Abortion Ban. (PubMed, Am J Prev Med) - "This study found evidence of increased infant mortality in Texas after the implementation of a six-week abortion ban with differential impact identified for Non-Hispanic Black infants in a comparison analysis. These results build on growing evidence and should guide and inform policy and public health interventions addressing increased infant mortality."

Journal

Abortion Wait Time Increases for Residents of an Abortion-Supportive State after Changing Abortion Legislation. (PubMed, J Womens Health (Larchmt)) - "Introduction: Since 2021, state legislative restrictions like Texas Senate Bill 8 (SB8), followed by the U.S. Supreme Court Dobbs v. Jackson Women's Health Organization (Dobbs) decision, led to a surge of people traveling for abortion care...This study highlights the importance of maintaining abortion access for state residents during an influx of out-of-state patients. This increase in wait time is especially disruptive in rural and underserved states where residents face significant baseline barriers to medical care."

Journal • Retrospective data • Women's Health

Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer (clinicaltrials.gov) - P1/2 | N=0 | Withdrawn | Sponsor: National Cancer Institute (NCI) | N=127 ➔ 0 | Not yet recruiting ➔ Withdrawn

Enrollment change • Trial withdrawal • Carcinosarcoma • Epithelial Ovarian Cancer • Fallopian Tube Cancer • High Grade Serous Ovarian Cancer • Oncology • Ovarian Cancer • Peritoneal Cancer • Refractory Ovarian Cancer • Sarcoma • Solid Tumor

Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer (clinicaltrials.gov) - P2 | N=349 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Mar 2025 ➔ Mar 2026

Trial completion date • Carcinosarcoma • Endometrial Adenocarcinoma • Endometrial Cancer • Endometrial Serous Adenocarcinoma • Oncology • Sarcoma • Solid Tumor • Uterine Cancer • AKT1

NRG-GY036: Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer (clinicaltrials.gov) - P3 | N=880 | Recruiting | Sponsor: NRG Oncology | Not yet recruiting ➔ Recruiting | Trial completion date: Dec 2035 ➔ Dec 2034

Enrollment open • Trial completion date • Fallopian Tube Cancer • High Grade Serous Ovarian Cancer • Oncology • Ovarian Cancer • Solid Tumor • BRCA

External Beam Radiation Therapy and Brachytherapy With Chemotherapy and Immunotherapy for the Treatment of Stage IVB Cervical Cancer (clinicaltrials.gov) - P1/2 | N=35 | Not yet recruiting | Sponsor: Jonsson Comprehensive Cancer Center | Trial completion date: Jan 2031 ➔ Jan 2032 | Initiation date: Jan 2025 ➔ Jan 2026 | Trial primary completion date: Jan 2030 ➔ Jan 2031

Trial completion date • Trial initiation date • Trial primary completion date • Cervical Adenocarcinoma • Cervical Cancer • Cervical Squamous Cell Carcinoma • Oncology • Solid Tumor • Squamous Cell Carcinoma

ECOG-ACRIN EA3202: Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers (clinicaltrials.gov) - P2/3 | N=430 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Recruiting ➔ Active, not recruiting

Checkpoint inhibition • Enrollment closed • IO biomarker • Head and Neck Cancer • Hypopharyngeal Cancer • Laryngeal Cancer • Lung Cancer • Nasopharyngeal Carcinoma • Oncology • Oral Cancer • Oropharyngeal Cancer • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • Squamous Cell Skin Cancer • PD-L1

Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer (clinicaltrials.gov) - P1 | N=24 | Recruiting | Sponsor: National Cancer Institute (NCI) | Not yet recruiting ➔ Recruiting | Trial completion date: Oct 2025 ➔ Dec 2026 | Initiation date: Apr 2025 ➔ Jan 2026 | Trial primary completion date: Oct 2025 ➔ Dec 2026

Enrollment open • Trial completion date • Trial initiation date • Trial primary completion date • Colorectal Adenocarcinoma • Colorectal Cancer • Oncology • Solid Tumor

NRG-GY009: Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov) - P2/3 | N=444 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Sep 2026 ➔ Mar 2026

Platinum resistant • Trial completion date • Fallopian Tube Cancer • High Grade Serous Ovarian Cancer • Oncology • Ovarian Cancer • Peritoneal Cancer • Solid Tumor • PD-L1

Mental Distress Among Females Following 2021 Abortion Restrictions in Texas. (PubMed, JAMA Netw Open) - "To quantify changes in frequent mental distress among females in Texas, following implementation of the 2021 Texas Heartbeat Act Senate Bill 8 (SB8), which banned abortions upon detection of embryonic cardiac activity...Disproportionately higher increases among younger people could be associated with higher levels of anticipated or actual need for abortion care or less ability to overcome barriers to care, including travel. These findings signal that state abortion policy may negatively affect mental health."

Journal • CNS Disorders • Mental Retardation • Psychiatry

Association of Reproductive Access Restrictions and Out-of-State Abortion Care in Colorado, an Interrupted Time Series Analysis for 2018-2024. (PubMed, Am J Obstet Gynecol) - "There has been a significant increase in the number of patients traveling to Colorado for abortions associated with changes to both federal and state laws, carrying implications for clinicians and patients alike. While some of the initial demand for abortions from out-of-state residents appears to have reduced in Colorado, it has not returned to baseline and may reflect a permanent shift in how and where abortion care is provided."

Journal • Women's Health

Geographic Realities of Abortion Access in Texas: Exploring the Heterogeneous Effects of Texas Senate Bill 8 with Mobile Phone Data. (PubMed, Popul Res Policy Rev) - "This study provides further evidence of the discriminatory impacts of SB8 in Texas. The online version contains supplementary material available at 10.1007/s11113-025-09948-0."

Heterogeneity • Journal

ECOG-ACRIN 5103: Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer (clinicaltrials.gov) - P3 | N=4994 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Feb 2025 ➔ Feb 2026

Trial completion date • Breast Cancer • HER2 Breast Cancer • Hormone Receptor Breast Cancer • Oncology • Solid Tumor • ER • HER-2

CALGB 40603: Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery (clinicaltrials.gov) - P2 | N=454 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Feb 2025 ➔ Feb 2026

Trial completion date • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Breast Cancer • Inflammatory Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • ER • HER-2 • PGR

Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer (clinicaltrials.gov) - P3 | N=50 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Mar 2025 ➔ Mar 2026

Trial completion date • Fallopian Tube Cancer • Oncology • Ovarian Cancer • Solid Tumor

Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov) - P3 | N=403 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Feb 2025 ➔ Feb 2026

Trial completion date • Head and Neck Cancer • Hypopharyngeal Cancer • Lung Cancer • Oncology • Oral Cancer • Oropharyngeal Cancer • Salivary Gland Cancer • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • Squamous Cell Carcinoma of Unknown Primary • Tongue Carcinoma

Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer, the COMMIT Study (clinicaltrials.gov) - P3 | N=120 | Suspended | Sponsor: National Cancer Institute (NCI) | Recruiting ➔ Suspended

Trial suspension • Colon Adenocarcinoma • Colon Cancer • Colorectal Adenocarcinoma • Colorectal Cancer • Microsatellite Instability • Oncology • Solid Tumor • MLH1 • MSH2 • MSH6 • MSI

S0533: Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery (clinicaltrials.gov) - P2 | N=29 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Feb 2025 ➔ Feb 2026

Trial completion date • Large Cell Carcinoma • Lung Adenocarcinoma • Lung Cancer • Lung Non-Small Cell Squamous Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma

A Study to Determine Whether Chemotherapy and Atezolizumab is Better Than Chemotherapy, Bevacizumab and Atezolizumab in Patients With Advanced Liver Cancer (clinicaltrials.gov) - P2 | N=88 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: May 2025 ➔ Dec 2025 | Trial primary completion date: May 2025 ➔ Dec 2025

Trial completion date • Trial primary completion date • Biliary Cancer • Cholangiocarcinoma • Hepatocellular Cancer • Hepatology • Liver Cancer • Oncology • Psoriatic Arthritis • Solid Tumor • IL2

Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery (clinicaltrials.gov) - P3 | N=1501 | Completed | Sponsor: National Cancer Institute (NCI) | Active, not recruiting ➔ Completed | Trial completion date: Oct 2025 ➔ Jan 2025

Trial completion • Trial completion date • Lung Cancer • Lung Non-Small Cell Squamous Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer (clinicaltrials.gov) - P2 | N=65 | Recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Dec 2024 ➔ Dec 2027 | Trial primary completion date: Dec 2024 ➔ Dec 2027

Trial completion date • Trial primary completion date • Genito-urinary Cancer • Kidney Cancer • Oncology • Papillary Renal Cell Carcinoma • Renal Cell Carcinoma • Solid Tumor

SWOG-S0518: Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor (clinicaltrials.gov) - P3 | N=427 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Jan 2025 ➔ Jan 2026

Trial completion date • Endocrine Cancer • Gastric Cancer • Neuroendocrine Tumor • Oncology • Solid Tumor • Thyroid Gland Carcinoma • Thyroid Gland Medullary Carcinoma